![Pancreatic cancer](https://assets.shortpedia.com/uploads/2022/11/07/1667810178.webp?tr=w-1200,h-600,cm-pad_resize,bg-F3F3F3)
According to Cleary, the KRAS gene, which causes about half of all human cancers, is mutated in more than 90% of cases of pancreatic cancer. However, a medication to turn off this specific gene has not yet been developed. One of oncology's "holy grails" is figuring out how to successfully target KRAS with a drug, according to Cleary. A Nobel Prize could be given to whoever develops an efficient KRAS targeted therapy because it is so crucial to oncology.